小RNA
医学
生物标志物
肺结核
免疫学
结核分枝杆菌
内科学
生物
病理
生物化学
作者
Shunsuke Uno,Tomoyasu Nishimura,Kazumi Nishio,Asami Kohsaka,Eiko Tamizu,Yukiko Nakano,Junko Kagyo,Yukiko Nakajima,Ryosuke Arai,Hirotsugu Hasegawa,Kenichi Arakawa,Shoko Kashimura,Ryota Ishii,Naoki Miyazaki,Yoshifumi Uwamino,Naoki Hasegawa
出处
期刊:Tuberculosis
[Elsevier]
日期:2021-07-01
卷期号:129: 102101-102101
被引量:6
标识
DOI:10.1016/j.tube.2021.102101
摘要
To determine the usefulness of hsa-miR-346, a potential biomarker enhancing the activity of non-tuberculous mycobacterial diseases, as a biomarker of tuberculosis activity.We investigated whether hsa-miR-346 is secreted by human macrophages infected with Mycobacterium tuberculosis (M. tuberculosis) in an in vitro study. In addition, a cross-sectional study was conducted first to evaluate whether serum hsa-miR-346 is elevated in patients with tuberculosis compared with that in healthy individuals. Second, we conducted a retrospective study to evaluate whether anti-tuberculosis treatment reduces serum hsa-miR-346 levels.Log hsa-miR-346 levels were significantly elevated in the supernatant of human macrophages infected with M. tuberculosis in a dose-dependent manner. The mean serum log hsa-miR-346 levels were -15.48 (-15.76 to -15.21) in patients with tuberculosis and -16.12 (-16.29 to -15.95) in healthy volunteers, which significantly differed. In addition, hsa-miR-346 significantly decreased at 2 months from starting an anti-tuberculosis treatment.We consider hsa-miR-346 as a potential biomarker enhancing the tuberculosis activity.
科研通智能强力驱动
Strongly Powered by AbleSci AI